Testosterone potentiated 32P therapy in prostatic carcinoma

Twelve patients with metastatic prostatic carcinoma and intractable bone pain were treated with testosterone potentiated 32P therapy. One patient expired prior to the completion of therapy; in the remaining 11 patients there was marked relief of pain allowing the discontinuance of narcotics for an a...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1966-08, Vol.19 (8), p.1088-1090
Main Authors: Donati, Robert M., Ellis, Harry, Gallagher, Neil I.
Format: Article
Language:English
Subjects:
Humans
Male
Palliative Care
Phosphorus Isotopes - therapeutic use
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - radiotherapy
Testosterone - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Twelve patients with metastatic prostatic carcinoma and intractable bone pain were treated with testosterone potentiated 32P therapy. One patient expired prior to the completion of therapy; in the remaining 11 patients there was marked relief of pain allowing the discontinuance of narcotics for an average period of 6.3 months. In 9 of the 11 patients radiographic improvement of osseous metastases was demonstrated. The authors conclude that testosterone potentiated 32P therapy is a valuable adjunct in the palliative therapy of metastatic osseous prostatic cancer.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(196608)19:8<1088::AID-CNCR2820190806>3.0.CO;2-O